Atul Pande, M.D
Atul Pande has a broad experience in strategic enterprise leadership of R&D with proven results as demonstrated by successful regulatory filings and approvals of new drugs.
Dr. Pande has experience in Neurosciences, Respiratory, HIV, Oncology and Cardiovascular therapy areas.
Suggested For You
perspectives
November 26th, 2024
Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs
perspectives
November 21st, 2024
Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success
news
November 19th, 2024
MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year
perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar
news
November 8th, 2024
MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance
perspectives
November 6th, 2024
How to Successfully Manage Rescue Studies and Turn Around Clinical Trials Facing Failure
perspectives
October 29th, 2024
Why Outsourcing QC of Regulatory and Medical Writing Documents is a Competitive Advantage for Large Pharma Companies
perspectives
October 22nd, 2024
Choosing the Right Clinical Trial Design: A Crucial Step in Protocol Development
perspectives
October 15th, 2024
Putting the Action in Diversity Action Plans and the Real-Time Data Visualization Technology Needed to Ensure It Happens
news
October 15th, 2024
MMS Recognized with EcoVadis Bronze Medal for Leadership in ESG Sustainability Efforts as a Leading Clinical Research Organization (CRO)
perspectives
October 8th, 2024
Diversity Action Plan Guidance Part I: Implications for Sponsors
webinar
October 22nd, 2024
Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules